Dramatic differences resulting from treatment timing of treprostinil in high-risk patients: a real-world data analysis

Back

ESC2025 Premium Access

Dramatic differences resulting from treatment timing of treprostinil in high-risk patients: a real-world data analysis

Session: Treatment of pulmonary hypertension

Topic: Pulmonary Hypertension

Speaker: Doctor Y. Kim (Seoul, KR)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Ye Chan Kim

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea (Republic of))

0 follower

6 more presentations in this session

Representativeness of randomized clinical trial criteria among the real-world patients with pulmonary arterial hypertension: an analysis from the FOCUS-PAH registry

Speaker: Doctor E. Bertarelli (Trieste, IT)

Comparison of triple oral and triple parenteral combination therapy in pulmonary arterial hypertension

Speaker: Doctor F. Chietera (Bologna, IT)

Pediatric pulmonary arterial hypertension: characteristics and efficacy of specific therapy on clinical, echocardiographic and hemodynamic parameters

Speaker: Doctor M. Salvi (Bologna, IT)

Hemodynamic effects of add-on therapies in pulmonary arterial hypertension: an additive component network meta-analysis.

Speaker: Mr I. Farmakis (Munich, DE)

Pulmonary artery denervation for pulmonary hypertension-a systematic review and meta-analysis

Speaker: Associate Professor E. Cekirdekci (Kyrenia, CY)

Access the full session

Treatment of pulmonary hypertension

Speakers: Doctor Y. Kim, Doctor E. Bertarelli, Doctor F. Chietera, Doctor M. Salvi, Mr I. Farmakis...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources